Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
British Ambassador to the United Nations: Calls on all parties to protect civilians and emphasizes restraint.
2025-06-20
British Ambassador to the United Nations: Calls on all parties to protect civilians and emphasizes restraint.
Back
Other News
2025-06-20
Ministry of Finance: From January to May, stamp tax revenue was 178.7 billion yuan, up 18.8% year-on-year, of which stamp tax revenue from securities transactions was 66.8 billion yuan, up 52.4% year-on-year.
Ministry of Finance: From January to May, stamp tax revenue was 178.7 billion yuan, up 18.8% year-on-year, of which stamp tax revenue from securities transactions was 66.8 billion yuan, up 52.4% year-on-year.
2025-06-20
[Bank of America raises Sino Biopharmaceutical target to HK$5.9 Reiterates buy] Bank of America Securities issued a report stating that Sino Biopharmaceutical (01177.HK) recently announced that a licensing transaction will be implemented, and the com
[Bank of America raises Sino Biopharmaceutical target to HK$5.9 Reiterates buy] Bank of America Securities issued a report stating that Sino Biopharmaceutical (01177.HK) recently announced that a licensing transaction will be implemented, and the company expects the sales proportion of innovative drugs to increase to more than 50% this year and reach 60% by 2027. The growth momentum is driven by the company's "internal research and development + external licensing" dual-engine strategy. In addition, the company recently received approval from the National Medical Products Administration for its Phase III clinical trial of TQC3721 for the treatment of chronic obstructive pulmonary disease (COPD). The bank took TQC3721's revenue forecast into consideration and raised Sino Biopharmaceutical's total revenue forecast for 2027 by 1%; the target price was raised from HK$5.1 to HK$5.9, and the "buy" rating was reiterated because the company's product pipeline is progressing smoothly.